Upgrade to SI Premium - Free Trial

Form SCHEDULE 13D/A THOMSON REUTERS CORP Filed by: Woodbridge CO LTD

April 17, 2026 9:21 PM





If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




schemaVersion:


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to rows 8 and 10 above, includes 300,790,959 common shares of Thomson Reuters Corporation ("Common Shares") beneficially owned by The Woodbridge Company Limited and subsidiaries and 11,727,129 Common Shares beneficially owned by the family of the late Roy H. Thomson, the first Lord Thomson of Fleet through various affiliated corporations. In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D


THOMSON INVESTMENTS LIMITED
Signature:/s/ Michael Medline
Name/Title:CEO & President
Date:04/17/2026
THE WOODBRIDGE COMPANY LIMITED
Signature:/s/ Michael Medline
Name/Title:CEO & President
Date:04/17/2026
1908720 ONTARIO LIMITED
Signature:/s/ Michael Medline
Name/Title:CEO & President
Date:04/17/2026
1000706525 ONTARIO LIMITED
Signature:/s/ Michael Medline
Name/Title:CEO & President
Date:04/17/2026
1396164 Ontario Limited
Signature:/s/ Michael Medline
Name/Title:CEO & President
Date:04/17/2026
1925124 Ontario Limited
Signature:/s/ Michael Medline
Name/Title:CEO & President
Date:04/17/2026
Woodbridge Investments Corporation
Signature:/s/ Michael Medline
Name/Title:CEO & President
Date:04/17/2026
KRT INVESTMENTS CORP.
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
DKRT FAMILY CORP.
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
DKRT INVESTMENTS CORP.
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
DKRT FUNDING CORP.
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
1000920847 ONTARIO LIMITED
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
MB FINANCE CORP.
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
TT INVESTMENTS CORP.
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
TLT INVESTMENTS CORP.
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
TLT ISSUE HOLDCO A CORP.
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
TLT ISSUE HOLDCO CORP.
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
1761173 ONTARIO LIMITED
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
2677295 ONTARIO LIMITED
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
1000919995 ONTARIO LIMITED
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
1754693 ONTARIO LIMITED
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
PJT INVESTMENTS CORP.
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
1000920848 ONTARIO LIMITED
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
PGF INVESTMENTS CORP.
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
PGF FAMILY CORP.
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
LCC INVESTMENTS CORP.
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
1000078931 ONTARIO LIMITED
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
1000421133 ONTARIO LIMITED
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
LLD INVESTMENTS CORP.
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
2806335 ONTARIO LIMITED
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
JRD INVESTMENTS CORP.
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
2754783 ONTARIO LIMITED
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
GED INVESTMENTS CORP.
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
SEG INVESTMENTS CORP.
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
1000031857 ONTARIO LIMITED
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
SEG FAMILY CORP.
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
TCM INVESTMENTS CORP.
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
DYM INVESTMENTS CORP.
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
BG INVESTMENTS CORP.
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
ACG INVESTMENTS CORP.
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
1001404651 ONTARIO LIMITED
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
2808194 ONTARIO LIMITED
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026

ATTACHMENTS / EXHIBITS

EXHIBIT 1

EXHIBIT 2

EXHIBIT 3

EXHIBIT 4

Categories

SEC Filings